Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa
Movement Disorders Clinical Practice · 2026
DOI: 10.1002/mdc3.70533 ↗Kurz gefasst
Fallbericht in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Maeve Bradley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dublin Neurological Institute at the Mater Misercordiae University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents, Disruptive, Impulse Control, and Conduct Disorders, Levodopa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Impulse control disorders (ICDs) are most often associated with dopamine agonists and pulsatile dopamine replacement therapy such as oral levodopa and subcutaneous apomorphine. Intestinal levodopa–carbidopa gel may improve ICDs through rationalization of dopaminergic agents and/or a reduction of pulsatile dopaminergic stimulation, however the impact of subcutaneous foslevodopa/foscarbidopa (CSFLI) has not been reported to date. Cases We describe five men aged 50–68 with advanced Parkinson's disease (PD) and pre‐existing ICDs who were switched to CSFLI. Four of them were transitioned directly from subcutaneous apomorphine infusions with the hope of improving ICD symptoms. All experienced worsening or persistent ICD symptoms, predominantly hypersexuality, after switching to CSFLI with a mean time to peak ICD symptoms of 4.5 weeks (range 2–6).
Conclusions
CSFLI may exacerbate ICDs in susceptible individuals. Pre‐treatment screening and close monitoring are recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dublin Neurological Institute at the Mater Misercordiae University Hospital, Dublin, Ireland.
- School of Medicine, University College Dublin, Dublin, Ireland.
- Health Affairs and School of Medicine, University College Dublin, Dublin, Ireland.
ORCID-Profile: Maeve Bradley, Eoghan Donlon
Zitieren
APA
Bradley, M., Donlon, E., Gallagher, A., Ruggieri, F., Inocentes, J., Rua, A. D., O'Keeffe, C., Lynch, T., Fearon, C., & Walsh, R. A. (2026). Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70533
Vancouver
Bradley M, Donlon E, Gallagher A, Ruggieri F, Inocentes J, Rua AD, et al. Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70533
BibTeX
@article{Bradley2026,
author = {Bradley, Maeve and Donlon, Eoghan and Gallagher, Amy and Ruggieri, Federica and Inocentes, John and Rua, Antonio Diaz and O'Keeffe, Clodagh and Lynch, Tim and Fearon, Conor and Walsh, Richard A},
title = {Persisting or Worsening Impulse Control Disorders in Parkinson's Disease Following a Switch to Subcutaneous Foslevodopa‐Foscarbidopa},
journal = {Movement Disorders Clinical Practice},
year = {2026},
doi = {10.1002/mdc3.70533}
}
EUVIMED